Macquarie Group
BEAM icon

Macquarie Group’s Beam Therapeutics BEAM Stock Holding History

Macquarie Group’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-510
Closed -$29.1K – 2146
2022
Q2 		$20K Hold
510
– – ﹤0.01% 2304
2022
Q1 		$29K Hold
510
– – ﹤0.01% 2299
2021
Q4 		$41K Buy
510
+262
+106% +$22.4K ﹤0.01% 2215
2021
Q3 		$22K Hold
248
– – ﹤0.01% 2435
2021
Q2 		$32K Hold
248
– – ﹤0.01% 2250
2021
Q1 		$20K Sell
248
-117
-32% -$11.1K ﹤0.01% 2276
2020
Q4 		$30K Hold
365
– – ﹤0.01% 2147
2020
Q3 		$9K Hold
365
– – ﹤0.01% 2289
2020
Q2 		$10K Buy
+365
New +$7.87K ﹤0.01% 2284

Other funds holding BEAM

ARK Investment Management
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Farallon Capital Management
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Macquarie Group's BEAM Position: Q3 2022 in Review

Macquarie Group sold out of Beam Therapeutics (BEAM) in Q3 2022, closing a stake of 510 shares — an estimated $29.1K sold.

Macquarie Group first reported a position in BEAM in Q2 2020 and held it in 9 quarters. The position peaked at $41K in Q4 2021. 224 funds tracked by Wall St. Rank hold BEAM as of Q3 2022.

  • Macquarie Group reported no remaining Beam Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Macquarie Group sold 510 Beam Therapeutics shares in Q3 2022, an estimated $29.1K.
  • Macquarie Group first reported a position in Beam Therapeutics in Q2 2020 and held it in 9 quarters.
  • Macquarie Group's Beam Therapeutics position peaked at $41K in Q4 2021.
  • 224 funds tracked by Wall St. Rank held Beam Therapeutics as of Q3 2022.

Based on Macquarie Group's 13F filing for Q3 2022, filed 14 Nov 2022.